PRLD

MKT CAP:$263M

Prelude Therapeutics Incorporated

Market Cap

$263M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.40+$1.67 (+61.17%)

Apr 23, 2026

Company Details

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials...

CEO

Krishna Vaddi

IPO Date

Sep 25, 2020

Website

www.preludetx.com

Key Metrics TTM

Revenue

$12M

+73.4% YoY

Net Income

-$99M

EPS (Diluted)

-$1.35

Free Cash Flow

-$56M

Revenue / Share

$0.19

Gross Margin

93.1%

Operating Margin

-861.3%

Net Margin

-819.6%

FCF Margin

-464.3%

P/S

21.6x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 10, 2026

$12M+73.4%EPS -$1.29

Q4 2025

Mar 10, 2026

$6M+41.0%EPS -$0.26

Q3 2025

Nov 12, 2025

$7M+116.7%EPS -$0.26

Q2 2025

Aug 14, 2025

$0EPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$30M
Q2 22	$0	$0	-$29M
Q3 22	$0	$0	-$30M
Q4 22	$0	$0	-$33M
Q1 23	$0	$0	-$29M
Q2 23	$0	$0	-$32M
Q3 23	$0	$0	-$33M
Q4 23	$0	-$331.0K	-$37M
Q1 24	$0	$0	-$34M
Q2 24	$0	$0	-$37M
Q3 24	$3M	$3M	-$34M
Q4 24	$4M	$4M	-$34M
Q1 25	$0	$0	-$35M
Q2 25	$0	$0	-$32M
Q3 25	$7M	$6M	-$20M
Q4 25	$6M	$5M	-$17M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	87.6x	—
Q4 24	37.5x	—
Q1 25	37.5x	—
Q2 25	37.5x	—
Q3 25	25.0x	—
Q4 25	21.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$22M	-$23M
Q2 22	-$18M	-$19M
Q3 22	-$20M	-$21M
Q4 22	-$23M	-$23M
Q1 23	-$30M	-$31M
Q2 23	-$28M	-$29M
Q3 23	-$26M	-$26M
Q4 23	-$24M	-$25M
Q1 24	-$32M	-$32M
Q2 24	-$23M	-$23M
Q3 24	-$27M	-$27M
Q4 24	-$21M	-$21M
Q1 25	-$34M	-$34M
Q2 25	-$26M	-$26M
Q3 25	-$19M	-$19M
Q4 25	$23M	$23M

Capital Expenditures

Quarter	CapEx
Q1 22	$952.0K
Q2 22	$758.0K
Q3 22	$916.0K
Q4 22	$393.0K
Q1 23	$810.0K
Q2 23	$983.0K
Q3 23	$591.0K
Q4 23	$1M
Q1 24	$289.0K
Q2 24	$359.0K
Q3 24	$63.0K
Q4 24	$53.0K
Q1 25	$47.0K
Q2 25	$20.0K
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+37.9%
Q2 22	—	+5.5%
Q3 22	—	-1.4%
Q4 22	—	+1.1%
Q1 23	—	-3.9%
Q2 23	—	+10.0%
Q3 23	—	+9.8%
Q4 23	—	+12.0%
Q1 24	—	+18.0%
Q2 24	—	+14.7%
Q3 24	—	+12.0%
Q4 24	—	+1.2%
Q1 25	—	+0.8%
Q2 25	—	-13.4%
Q3 25	+116.7%	-28.0%
Q4 25	+41.0%	-39.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$6M	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$7M	—
Q4 23	$6M	—
Q1 24	$6M	—
Q2 24	$6M	—
Q3 24	$12M	400.6%
Q4 24	$4M	94.3%
Q1 25	$4M	—
Q2 25	$4M	—
Q3 25	$2M	37.3%
Q4 25	$2M	32.7%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$23M	$7M	—
Q2 22	$21M	$8M	—
Q3 22	$23M	$8M	—
Q4 22	$26M	$8M	—
Q1 23	$22M	$7M	—
Q2 23	$25M	$7M	—
Q3 23	$26M	$7M	—
Q4 23	$30M	—	$7M
Q1 24	$27M	$7M	—
Q2 24	$30M	$8M	—
Q3 24	$29M	$8M	—
Q4 24	$32M	$6M	—
Q1 25	$29M	$6M	—
Q2 25	$26M	$6M	—
Q3 25	$22M	—	$5M
Q4 25	$18M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$52M	$215M	$266M
Q2 22	$51M	$196M	$246M
Q3 22	$52M	$172M	$224M
Q4 22	$31M	$171M	$202M
Q1 23	$18M	$154M	$172M
Q2 23	$26M	$229M	$255M
Q3 23	$16M	$215M	$231M
Q4 23	$25M	$208M	$233M
Q1 24	$25M	$177M	$202M
Q2 24	$28M	$152M	$180M
Q3 24	$11M	$142M	$154M
Q4 24	$12M	$121M	$134M
Q1 25	$40M	$59M	$99M
Q2 25	$26M	$47M	$73M
Q3 25	$48M	$7M	$55M
Q4 25	$35M	$68M	$103M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	47M	+1.6%	+4.3%
Q2 22	47M	+0.4%	+2.6%
Q3 22	47M	+0.4%	+2.4%
Q4 22	48M	+0.9%	+3.4%
Q1 23	48M	-0.3%	+1.4%
Q2 23	56M	+17.8%	+19.0%
Q3 23	68M	+20.3%	+42.6%
Q4 23	70M	+2.9%	+45.3%
Q1 24	76M	+8.8%	+58.7%
Q2 24	76M	+0.0%	+34.7%
Q3 24	76M	+0.1%	+12.1%
Q4 24	76M	+0.1%	+9.1%
Q1 25	76M	+0.1%	+0.3%
Q2 25	76M	+0.0%	+0.3%
Q3 25	76M	+0.2%	+0.4%
Q4 25	63M	-17.3%	-17.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	116
Q2 22	$0	116
Q3 22	$0	116
Q4 22	$0	122
Q1 23	$0	122
Q2 23	$0	122
Q3 23	$0	122
Q4 23	$0	128
Q1 24	$0	128
Q2 24	$0	128
Q3 24	$23.4K	128
Q4 24	$30.5K	131
Q1 25	$0	131
Q2 25	$0	131
Q3 25	$49.6K	131
Q4 25	$28	200K

Revenue / Employee